Back to top

Curis doses first five patients in TakeAim CLL study

Curis (CRIS) announced an enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia, or CLL. Curis has achieved t...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Curis, Inc. (CRIS)